|
Faculty
 |
 |
John O. Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York |
Sandra Kurtin, PhD, ANP-C, AOCN
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona |
Program Overview
Three JAK inhibitors are now approved for the treatment of intermediate- to high-risk MF with trials demonstrating improvement in spleen volume, disease symptoms, and quality of life. However, at the same time, data shows that there is a high frequency of discontinuation because of either adverse events or, more frequently, progressive disease that lead to poor outcomes with survival after ruxolitinib discontinuation. The faculty will review the clinical practice considerations for the use of new second-line therapies for the treatment of myelofibrosis and touch on data emerging from clinical trials in the second-line setting. In this presentation, Dr. Mascarenhas and Dr. Kurtin review a series of case scenarios to demonstrate selecting the most appropriate treatment for specific patient populations from the available options. Additionally, these experts share recommendations for shared decision-making and the importance of patient education.
This program will conclude with a live question and answer session. Don’t miss the opportunity to ask your questions or share your clinical challenges directly with the experts.
Agenda
| 10 minutes |
Shared Decision-Making (SDM) in Myelofibrosis |
| 15 minutes |
Case-Presentations: Applying SDM to Practice |
| 5 minutes |
Audience Q & A |
Target Audience
This activity is designed for hematologists, hematologist/oncologists, nurses, advanced practice providers including nurses, and pharmacists who provide care to patients with myelofibrosis.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Align patient presentation and symptomatology with second-line options in MF through a series of case scenarios
- Outline importance and role of shared decision-making and patient/care giver education in the treatment of MF
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME)
.
 |
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of Nursing Continuing Professional Development by The American Nurses Credentialing Center’s Commission on Accreditation.
The University of Texas MD Anderson Cancer Center designates this live activity and will award 0.50 Nursing Continuing Professional Development (NCPD) contact hours. |
 |
CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-022-L01-P. Knowledge-based
CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
|
|
Disclosure
The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
As an organization accredited by the Accreditation Council for Pharmacy Education (ACPE), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company.
Faculty Disclosures
Dr. John Mascarenhas has relevant financial relationships related to consulting from AbbVie Inc., Bristol Myers Squibb Company, Celgene Corporation ‒ A Bristol Myers Squibb Company, Constellation Pharmaceuticals, CTI BioPharma Corp., F. Hoffmann-La Roche Ltd, Incyte Corporation, Galecto Biotech, GlaxoSmithKline plc, Geron, Imago BioSciences, Kartos Therapeutics, Inc., Novartis AG, PharmaEssentia Corporation, and Sierra Oncology, Inc. He serves on the Data and Safety Monitoring Board (DSMB) for Karyopharm Therapeutics.
Dr. Sandra Kurtin has relevant financial relationships related to consulting from AbbVie Inc., Amgen Inc., AstraZeneca, Bristol Myers Squibb Company, Epizyme, Inc., GlaxoSmithKline plc, Incyte Corporation, Pharmacyclics, Inc., and Takeda Oncology.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity
contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience
the discussion of off-label or investigational uses of products or devices.
|
Planning Committee
The following planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
MediCom Worldwide, Inc.: Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager
The University of Texas MD Anderson Cancer Center: Tamara Greiner, MA, Associate Director, and Danya Garner, MSN, Associate Director, CPE
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
There are no fees for participating in this activity.
A post activity evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.
In order to receive credit, all participants must complete the self-assessment post-test and evaluation within 14 days of completing the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.
CME, NCPD, and CE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation
If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x114 or [email protected]. |
|
|
| Provided by |
|
and |
 |
|
| Supported by educational grants from Bristol Myers Squibb Company,
CTI BioPharma, and Sierra Oncology. |
|
|
|
|
